Skip to main content
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Subscribe
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Cori Gray, PharmD
Authored Items
Outcomes-Based Contracting for Disease-Modifying Therapies in Multiple Sclerosis: Necessary Conditions for Paradigm Adoption
Cori Gray, PharmD
,
Gary Branning, MBA
,
James T. Kenney, RPh, MBA
December 2019 Vol 12, No 8
in
Original Research
,
Practice Management
Evolution of the Medicare Part D Medication Therapy Management Program from Inception in 2006 to the Present
Cori Gray, PharmD
,
Jack E. Fincham, PhD, RPh
,
Catherine E. Cooke, PharmD, MS (PHSR), BCPS, PAHM
,
Nicole Brandt, PharmD, MBA, BCPP, BCGP, FASCP
September 2019 Vol 12, No 5
in
Review Article
,
Practice Management
Last modified: September 17, 2019
